Impact of first dose of BNT162b2 vaccine on COVID-19 infection among healthcare workers in an Irish hospital

Jennifer Walsh1 · Mairead Skally1 · Leah Traynor2 · Eoghan de Barra3,4 · Aoife Ni Dhuthaigh2 · Blanaid Hayes2 · Fidelma Fitzpatrick1,5

Received: 18 May 2021 / Accepted: 21 May 2021 / Published online: 27 May 2021
© Royal Academy of Medicine in Ireland 2021

Keywords COVID-19 · Healthcare worker · SARS-CoV 2 · Vaccination

Dear Editor,

The coronavirus disease 2019 (COVID-19) pandemic has had a significant and disproportionate impact on healthcare workers (HCWs) [1, 2]. In Ireland, from the start of the pandemic to week 15, 2021, 28,407 (11.6%) of 244,083 COVID-19 cases were among HCWs. Of these, 775 (2.7%) were hospitalized, 101 (0.3%) were admitted to critical care, and 17 HCWs died [3]. On the 21st of December 2020, the European Medicines Agency granted authorisation of the BNT162b2 vaccine, an mRNA vaccine produced by Pfizer Inc. and BioNTech administered as two doses. A variety of public health strategies for optimal pandemic control have been proposed including rapidly increasing the number of vaccinated individuals by halving doses or prolonging dosing intervals or concentrating available vaccine doses to specific at-risk patient groups [4]. Early reports from national vaccination campaigns have reported a significant improvement in COVID-19-related health outcomes after a single vaccination [5].

We report our experience of the impact of COVID-19 vaccination among HCWs in our institution during the first 8 weeks of the staff vaccination programme, in particular following the administration of the first dose of a two-dose schedule (BNT162b2 vaccine, two doses administered intramuscularly 21 days apart). The study population incorporated all permanently employed HCWs at the hospital (n = 4458). Staff vaccination commenced on 29 December 2020 at a time when the national incidence of COVID-19 was rising rapidly into the third wave. The third COVID-19 wave had a significant impact in Ireland, with over 40% of all deaths and over 50% of COVID-19 cases recorded from 1 January to 15 February 2021 [6]. The majority of HCWs received their first dose during the 8-week study period with some also receiving their second dose. We retrospectively reviewed the rates of COVID-19 among staff vaccinated with their first vaccine dose and unvaccinated staff between the 29th December 2020 and the 22nd February 2021.

The majority of staff (85%) received their first-dose vaccination over the study period (Table 1). During the study period, 1708 staff (38%) had a COVID-19 test, 1314 (77%) of which were known to have received their first vaccine dose. Positivity rates between the vaccinated and unvaccinated groups differed significantly with 5.8% of the vaccinated cohort testing COVID-19-positive versus 25.6% of those tested in the unvaccinated cohort (OR 0.18, C.I. 0.13–0.25, p < 0.01). Review of COVID-19 positive cases showed that the most common indication for SARS-CoV 2 testing in both vaccinated and unvaccinated HCWs was COVID-19 symptoms (49% vaccinated cohort and 61% unvaccinated cohort respectively); however, the unvaccinated cohort had a greater proportion of symptomatic staff, followed by close contact follow-up testing (29% and 22%). The majority of positive PCR results in vaccinated staff (65/77, 84.4%) were in the 14 days following their first dose vaccination. As evidenced by Table 1, a greater proportion

---

Jennifer Walsh
Jenniferwalsh@beaumont.ie

1 Department of Microbiology, Beaumont Hospital, Dublin, Ireland
2 Occupational Health Department, Beaumont Hospital, Dublin, Ireland
3 Department of Infectious Diseases, Beaumont Hospital, Dublin, Ireland
4 Dept. of International Health and Tropical Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
5 Department of Clinical Microbiology, Royal College of Surgeons in Ireland, Dublin, Ireland
of unvaccinated HCWs were tested, COVID-19 positive and symptomatic.

The impact of a single vaccination in HCWs has been noted in the UK (single dose of BNT162b2 vaccine demonstrated vaccine effectiveness of 72%) and in the USA (2.61% COVID-19 in unvaccinated HCW, 1.82% in partially vaccinated HCW, and 0.05% in fully vaccinated HCW) [7, 8]. Our experience reflects the positive impact of vaccination on COVID-19 incidence, even in those who are partially vaccinated. The implementation of HCW vaccination in Ireland has been reflected with a decreasing proportion of HCW COVID-19 cases in national reports in the first 3 months of 2021 [3]. In addition to reducing SARS-CoV-2 acquisition and transmission, COVID-19 vaccination preserves the HCW workforce at a time when it is most required, with reductions in the generation of HCW COVID-19 cases and close contacts. While our study is limited by its retrospective nature, the differing HCW PCR positivity rates between vaccinated and unvaccinated HCWs, even after a single vaccination, highlight the key role of COVID-19 vaccination in this pandemic, and the importance of rapid first dose roll out, not just in HCWs but also in the Irish population as a whole.

| Indications for testing               | BNT162b2 first dose vaccination (n=3805, 85%) | Not vaccinated (n=653, 15%) |
|--------------------------------------|---------------------------------------------|-----------------------------|
| SARS-CoV 2 PCR performed             | 1314 (34%)                                  | 394 (56.8%)                 |
| SARS CoV 2 PCR positive              | 77 (5.8%)                                   | 101 (25.6%)                 |
| COVID-19 symptoms                    | 38 (49%)                                    | 62 (61%)                    |
| Close contact status                 | 22 (29%)                                    | 22 (22%)                    |
| Asymptomatic screening               | 13 (17%)                                    | 11 (11%)                    |
| Not documented                       | 4 (5%)                                      | 6 (6%)                      |
| Duration between 1st dose vaccine and positive PCR |                                    |                            |
| 0–7 days                             | 26                                           | N/A                         |
| 8–14 days                            | 39                                           | 5                           |
| 15–21 days                           | 5                                            | 6                           |
| 22–30 days                           | 6                                            | 1                           |
| 39 days                              | 1                                            | 0                           |

**Table 1** Demographics, SARS-CoV2 testing, BNT162b2 first dose vaccination and COVID-19 of 4458 healthcare staff from 29 December 2020 to 22 February 2021

**Declarations**

**Ethical approval** This research was conducted retrospectively from data obtained for clinical purposes. It was registered with the Clinical Governance Department at Beaumont Hospital under the registration number CA2021/120.

**Conflict of interest** The authors declare that they have no conflict of interest.

**References**

1. Mehta S, Machado F, Kwizera A (2021) Covid-19: a heavy toll on health-care workers, Lancet Respir Med 9(3):226–228. https://doi.org/10.1016/S2213-2600(21)00068-0
2. Nguyen LH, Drew DA, Graham MS (2020) Risk of Covid-19 among front-line health-care workers and the general community: a prospective cohort study. Lancet Public Health 5(9):E475–E483. https://doi.org/10.1016/S2468-2667(20)30164-X
3. Health Protection Surveillance Centre (2021) Report of the profile of COVID-19 cases in healthcare workers in Ireland week 48, 2020 (22/11/2020–28/11/2020) - week 15, 2021 (11/04/21–17/04/21) (https://www.hpsc.ie/a-Z/respiratory/coronavirus/novelcoronavirus/surveillance/covid19casesinhealthcareworkers/COVID-19_HCW_weekly_report_20%2004%202021_v1.0_website%20version.pdf)
4. Cobey S, Larremore DB, Grad YH (2021) Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination. Nat Rev Immunol 21:330–335. https://doi.org/10.1038/s41577-021-00544-9
5. Dagan N, Barda N, Kepten E (2021) BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 384:1412–1423. https://doi.org/10.1056/NEJMoa2101765
6. Valesca L (2021) The pandemic one year on: trends and statistics between three waves of the COVID-19 pandemic in Ireland. https://publicpolicy.ie/papers/the-pandemic-one-year-on-trends-and-statistics-between-three-waves-of-the-covid-19-pandemic-in-ireland/
7. Hall VI, Foulkes S, Saei A et al (2021) Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England Multicentre Prospective Cohort Study (the SIREN Study). Lancet preprint. https://ssrn.com/abstract=3790399
8. Daniel W, Nivet M, Warner J (2021) Early evidence of the effect of SARS-CoV-2 vaccine at one medical center. N Engl J Med. https://doi.org/10.1056/NEJMc2102153